Mark J. Gergen - 26 Nov 2024 Form 4 Insider Report for Poseida Therapeutics, Inc.

Signature
/s/ Harry J. Leonhardt, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
26 Nov 2024
Net transactions value
-$194,670
Form type
4
Filing time
27 Nov 2024, 19:39:26 UTC
Previous filing
04 Mar 2024
Next filing
11 Dec 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PSTX Common Stock Options Exercise $83,430 +30,000 +4.6% $2.78 681,291 26 Nov 2024 Direct F1
transaction PSTX Common Stock Sale $278,100 -30,000 -4.4% $9.27* 651,291 26 Nov 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PSTX Employee Stock Option (Right to Buy) Options Exercise $0 -30,000 -19% $0.000000 126,372 26 Nov 2024 Common Stock 30,000 $2.78 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The option exercise and sale reported in this Form 4 were effected pusuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 21, 2024.
F2 The stock option is fully vested and exerciseable.